Parker Robert K, Connelly Neil Roy, Lucas Tanya, Serban Stelian, Pristas Rene, Berman Evan, Gibson Charles
Department of Anesthesiology, Baystate Medical Center, Springfield, MA, USA.
J Anesth. 2007;21(2):142-7. doi: 10.1007/s00540-006-0476-8. Epub 2007 May 30.
Many obstetric patients receiving epidural analgesia are encouraged to ambulate. This current study was designed to determine the potential for maximizing the time to first epidural supplement when adding clonidine to a 0.625 mg.ml(-1) bupivacaine continuous epidural infusion following epidural fentanyl bolus in early labor for patients allowed to ambulate. Maternal and fetal effects secondary to clonidine were also evaluated.
Sixty-eight laboring primigravid women received a 3-ml epidural test dose of lidocaine with epinephrine, followed by a fentanyl 100-microg bolus (in a 10 ml-volume). The patients then received a 0.625 mg.ml(-1) bupivacaine continuous epidural infusion, either with or without clonidine (5 microg.ml(-1)), at a rate of 10 ml.h(-1). Pain scores and side effects were recorded for each patient.
The overall quality of analgesia was similar in both groups. The mean duration prior to request for additional analgesia was significantly longer in the clonidine group (269 +/- 160 min), compared to the control group (164 +/- 64 min). No patient in either group experienced any detectable motor block; one patient (clonidine group) complained of mild thigh numbness and was not allowed to ambulate. While mean blood pressure was approximately 6 mmHg lower in the clonidine group at 1, 1.5, and 3.5 h, this was not clinically significant. No adverse effects on maternal heart rate or fetal heart rate were noted.
In early laboring patients, addition of clonidine prolongs the analgesia duration of a 0.625 mg.ml(-1) bupivacaine continuous epidural infusion following 100 microg epidural fentanyl (after a lidocaine-epinephrine test dose) without a clinically significant increase in side effects.
许多接受硬膜外镇痛的产科患者被鼓励下床活动。本研究旨在确定在分娩早期允许下床活动的患者中,在硬膜外注射芬太尼后,将可乐定添加到0.625mg/ml布比卡因持续硬膜外输注中时,首次硬膜外补充剂的最长使用时间的潜力。还评估了可乐定对母婴的影响。
68名初产妇在分娩时接受了3ml含肾上腺素的利多卡因硬膜外试验剂量,随后给予100μg芬太尼大剂量注射(10ml体积)。然后,患者以10ml/h的速度接受0.625mg/ml布比卡因持续硬膜外输注,其中一组添加可乐定(5μg/ml),另一组不添加。记录每位患者的疼痛评分和副作用。
两组的总体镇痛质量相似。与对照组(164±64分钟)相比,可乐定组在要求追加镇痛前的平均持续时间明显更长(269±160分钟)。两组均无患者出现可检测到的运动阻滞;一名患者(可乐定组)抱怨大腿轻度麻木,未被允许下床活动。虽然可乐定组在1、1.5和3.5小时时平均血压约低6mmHg,但这在临床上并不显著。未观察到对母体心率或胎儿心率的不良影响。
在分娩早期患者中,添加可乐定可延长在硬膜外注射100μg芬太尼(在利多卡因-肾上腺素试验剂量后)后0.625mg/ml布比卡因持续硬膜外输注的镇痛持续时间,且副作用无临床显著增加。